CLOs on the Move

Vera Therapeutics

www.veratx.com

 
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.veratx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.770.0077

Executives

Name Title Contact Details

Similar Companies

Kenney Orthopedics

Restoring Motion – Empowering Lives. Kenney Orthopedics, LLC, is committed to providing quality orthopedic and prosthetic related products and services.

Pharmaceutical Associates

Pharmaceutical Associates is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaVo Kerr

KaVo Kerr is a dental equipment manufacturer group that was spun off from Danaher Corporation.

Cerebral

At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient outcomes for years to come. With a heavy focus on clinical quality and safety in all that we do, we`ve accomplished excellent patient outcomes: • 82% of patients report an improvement in their anxiety symptoms after using Cerebral. • 75% of patients who report improvement in their depression see improvement within 60 days. • 50% of patients who initially report suicidal ideation no longer harbor suicidal thoughts after treatment with Cerebral. This is just the beginning for Cerebral, and we won`t stop building, growing, and iterating until everyone, everywhere can access high-quality evidence-based mental health care without high costs and/or long wait times. We`re looking for mission-driven leaders who share these values, and we need your help as we transform access to high-quality mental health care in the United States and beyond.

Egalet

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.